- Home
- DMAC
as 11-08-2024 10:33am EST
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Upcoming Earnings Alert:
Get ready for potential market movements as DiaMedica Therapeutics Inc. DMAC prepares to release earnings report on 13 Nov 2024.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 185.1M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 34.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.12 - $4.95 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest DiaMedica Therapeutics Inc. News
DMAC Breaking Stock News: Dive into DMAC Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
Zacks
25 days ago
Best Momentum Stocks to Buy for October 14th
Clinical Trials Arena
a month ago
DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial
MT Newswires
a month ago
DiaMedica Says It Receives South Africa Approval to Start Mid-Stage Trial for Preeclampsia Treatment
Business Wire
a month ago
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Simply Wall St.
a month ago
DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05m
Business Wire
2 months ago
DiaMedica Therapeutics Upcoming Conference Participation
Zacks
2 months ago
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Compare DMAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DMAC DiaMedica Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.